Vortex BioSciences, Inc. is developing a novel liquid biopsy technology that could revolutionize cancer diagnosis, monitoring and treatment.
Circulating Tumor Cells (CTCs) are cancer cells, which have detached from the primary cancer tumors and have entered the patient bloodstream. The number and type of circulating tumor cells (CTCs) in a patient blood is highly indicative of the status of cancer in that patient, and provides insight into the source of the primary tumor, grade, invasiveness, response to therapy and recurrence. CTCs are also the key cause of secondary cancers or metastasis in patients. As a result, the ability to identify and monitor CTCs in a patient blood can prove to be an integral part of cancer patient diagnosis, treatment and monitoring.
Vortex BioSciences, Inc. is a subsidiary of NetScientific, incorporated in 2012 and now based in Menlo Park, California. Vortex technology was formerly developed at UCLA Bioengineering by Pr. Dino Di Carlo. Vortex Team includes expertise in diagnostics, microfluidics, manufacturing and commercialization.